National consumption of antimicrobials in Tanzania: 2020-2022.

Background: The Global Leaders Group on Antimicrobial Resistance (AMR) beckoned nations to share surveillance data on antimicrobial consumption (AMC) and AMR while promoting access to essential antimicrobials in countries with the highest burden of AMR.

Objectives: To analyse findings of the national-level AMC (years 2020-2022), building on our prior work (2017-2019), and to assess any emerging trends.

Methods: Data were obtained from the Tanzania Medicines and Medical Devices Authority, Tanzania Medical Stores Department, and from local manufacturers.

A Comprehensive Assessment of Quality of Antimalarial Medicines in Mainland Tanzania: Insights from Five Years of Postmarket Surveillance.

Sustainable access to high-quality antimalarial medicines is pivotal to achieving universal and effective malaria control. Poor-quality antimalarial medicines are prevalent in sub-Saharan Africa, impeding malaria control initiatives and claiming the lives of many children. Regular monitoring of the quality of antimalarial medicines is crucial to ensure the quality of service to the community.

Incidence and determinants of adverse events in individuals with HIV commencing Dolutegravir-based antiretroviral therapy in mainland Tanzania.

Tanzania adopted a Dolutegravir (DTG)-based regimen as first-line treatment in 2019 following the World Health Organization recommendation. Data on the DTG safety profile from sub-Saharan Africa including Tanzania are limited. We investigated the incidence of DTG-related adverse events (AEs) and associated factors among people living with HIV (PLHIV) initiated on a DTG regimen.